Celgene Corporation (NASDAQ:CELG) PT Lowered to $102.00

Celgene Corporation (NASDAQ:CELG) had its price objective reduced by Citigroup Inc. from $140.00 to $102.00 in a research note released on Friday, October 27th. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on CELG. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $175.00 price objective on shares of Celgene Corporation in a research note on Wednesday, August 9th. Vetr upgraded shares of Celgene Corporation from a buy rating to a strong-buy rating and set a $148.32 price objective for the company in a research note on Wednesday, August 16th. Cantor Fitzgerald reiterated a buy rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Tuesday, September 26th. SunTrust Banks, Inc. reissued a buy rating and set a $150.00 target price on shares of Celgene Corporation in a research report on Friday, July 14th. Finally, Jefferies Group LLC reissued a buy rating and set a $160.00 target price on shares of Celgene Corporation in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $139.64.

Shares of Celgene Corporation (CELG) opened at $102.34 on Friday. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a market cap of $80,574.02, a PE ratio of 15.99, a PEG ratio of 0.79 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. research analysts predict that Celgene Corporation will post 6.67 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/celgene-corporation-celg-price-target-cut-to-102-00.html.

In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock valued at $2,843,956 over the last three months. 0.95% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of CELG. Marvin & Palmer Associates Inc. bought a new position in shares of Celgene Corporation during the third quarter valued at $3,538,000. Zeke Capital Advisors LLC lifted its holdings in shares of Celgene Corporation by 129.4% during the third quarter. Zeke Capital Advisors LLC now owns 13,135 shares of the biopharmaceutical company’s stock valued at $1,915,000 after acquiring an additional 7,410 shares during the period. Amalgamated Bank lifted its holdings in shares of Celgene Corporation by 2.3% during the third quarter. Amalgamated Bank now owns 93,591 shares of the biopharmaceutical company’s stock valued at $13,647,000 after acquiring an additional 2,140 shares during the period. Twin Capital Management Inc. lifted its holdings in shares of Celgene Corporation by 12.3% during the third quarter. Twin Capital Management Inc. now owns 51,560 shares of the biopharmaceutical company’s stock valued at $7,518,000 after acquiring an additional 5,660 shares during the period. Finally, Dai Ichi Life Insurance Company Ltd lifted its holdings in shares of Celgene Corporation by 14.9% during the third quarter. Dai Ichi Life Insurance Company Ltd now owns 117,188 shares of the biopharmaceutical company’s stock valued at $17,088,000 after acquiring an additional 15,165 shares during the period. 78.92% of the stock is owned by institutional investors.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply